Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity

• Published in: Health and quality of life outcomes 2019-06, Vol.17 (1), p.99-99, Article 99
• Main Authors: Askanase, Anca D, Daly, R Paola, Okado, Miya, Neville, Kayla, Pong, Avery, Hanrahan, Leslie M, Merrill, Joan T
• Format: Article
• Language: English
• Subjects: Adult; Analysis; Arthralgia; Arthritis; Autoimmune diseases; Chronic pain; Clinical outcomes; Clinical trials; Cognitive ability; Damage assessment; Development and progression; Disease activity; Drafting software; Experience; Fatigue; Female; Fever; Humans; Laboratories; Lupus; Lupus Erythematosus, Systemic - physiopathology; Lupus Erythematosus, Systemic - psychology; Male; Mapping; Measure; Measuring instruments; Medical research; Middle Aged; Pain; Patient Reported Outcome Measures; Patients; Physicians; PRO; Qualitative analysis; Qualitative Research; Quality of Life; Reproducibility of Results; Signs and symptoms; SLE; Stiffness; Surveys and Questionnaires; Systemic lupus erythematosus; Validity; Visual Analog Scale
• ISSN: 1477-7525; 1477-7525
• DOI: 10.1186/s12955-019-1151-8

The LFA REAL™ is a measurement system for evaluating lupus disease activity from both clinician and patient perspectives. Patients' viewpoints are captured using a patient-reported outcome (PRO) questionnaire. A series of visual analog scales are designed to rate disease severity and progress over the past 4 weeks. Brief instructions guide the patient to distinguish between active, potentially reversible symptoms and chronic pain or discomfort that are more likely due to damage. Beyond its simplicity and efficiency, the PRO can provide versatile assessments from a global, organ-based, and symptom-specific level. This paper describes the patient-centered approach used to evaluate the content validity of the LFA-REAL PRO. The PRO was developed in accordance with FDA guidance. A two-phase qualitative study was performed with 25 lupus patients, 10 who participated in concept elicitation (Phase 1) and 15 in cognitive debriefing interviews (Phase 2). Qualitative data were analyzed using ATLAS.ti software v7.5. Upon completion of the interviews, participants completed the draft PRO and additional measures to characterize the sample. The mean age of participants was 45.6 and 88% were female, as expected in a lupus population. The mean SF-36 physical component score was 29.8 and the mean mental component score was 46.4. Phase 1 elicited symptom saturation and mapping of the draft PRO. Fatigue was reported by 100% of patients, highlighting its importance as a measurable domain. Additionally, 100% of patients spontaneously mentioned arthritis, which may be more important to this group than previously estimated, substantiating the approach of this PRO to break down components of arthritis into joint pain, stiffness, and swelling. Shortness of breath and fever were reported more frequently than expected. Phase 2 data demonstrated that participants found the instrument easy to use and offered recommendations to improve clarity, leading to adjustments in wording and formatting. Results suggest that the LFA-REAL PRO has content validity and, with some modifications suggested by participants, is ready for quantitative validation, including tests of reliability, validity, responsiveness to change, and performance relative to other PROs used in lupus trials. After validation, the LFA-REAL system is intended for use in clinical practice and research.